ReviewNature reviews. Nephrology2015
Management of hypertension in chronic kidney disease.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Chronotherapy for hypertension in patients with chronic kidney disease: a systematic review and meta-analysis in non-black patients.International urology and nephrology · 2017Pooled it
- Loss of nighttime blood pressure dipping as a risk factor for coronary artery calcification in nondialysis chronic kidney disease.Medicine · 2017Trial
- Microbes and GFR in Health and CKD in Mice.Journal of the American Society of Nephrology : JASN · 2026Article
- Association of gut microbiome signatures with iron metabolism response to roxadustat in peritoneal dialysis patients with anemia: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Cross-sectional Survey of Hypertension Management among Patients Stratified by Chronic Kidney Disease in Japan.JMA journal · 2025Article
- Comparison of renal effects between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension and chronic kidney disease in Japan.Clinical and experimental nephrology · 2025Article
- Toll-like receptor 4 mutation mitigates gut microbiota-mediated hypertensive kidney injury.Pharmacological research · 2024Article
- Effects of ACE inhibitor/ARB therapy and long COVID on kidney disease: a retrospective cohort study using real-world data.Clinical kidney journal · 2024Article
- Self-Reported Frequency of Adding Salt to Food and Risk of Incident Chronic Kidney Disease.JAMA network open · 2023Article
- Tamoxifen associated to the conservative CKD treatment promoted additional antifibrotic effects on experimental hypertensive nephrosclerosis.Scientific reports · 2023Article
- Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease.Frontiers in endocrinology · 2023Review
- 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.Acta Cardiologica Sinica · 2022Article
- Serum Metabolites Associated with Blood Pressure in Chronic Kidney Disease Patients.Metabolites · 2022Article
- RNA-binding proteins and their role in kidney disease.Nature reviews. Nephrology · 2022Review
- Identification of biomarkers, pathways and potential therapeutic agents for salt-sensitive hypertension using RNA-seq.Frontiers in cardiovascular medicine · 2022Article
- NCC regulation by WNK signal cascade.Frontiers in physiology · 2022Review
- Hypertension in chronic kidney disease: What lies behind the scene.Frontiers in pharmacology · 2022Review
- SPRINT-A Kidney-Centric Narrative Review: Recent Advances in Hypertension.Hypertension (Dallas, Tex. : 1979) · 2021Review
- Recent advances in the management of secondary hypertension: chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a common comorbidity in patients with impaired kidney function. The kidney exerts a marked degree of control over blood pressure through various mechanisms, such as by regulating sodium balance and hormone secretion through the activity of the renin-angiotensin system. The kidney is susceptible to injury, and if already damaged can be at risk of further loss of function as a consequence of elevated blood pressure. Once elevated blood pressure is identified, a combination of sensible lifestyle measures, such as sodium restriction and weight loss, with pharmacological intervention to reduce blood pressure will usually achieve blood pressure goals. In this Review, we outline the importance of blood pressure control for patients with chronic kidney disease (CKD), the mechanisms that affect blood pressure control, and the basis for non-drug and drug therapies. We further discuss the rationale for <140 mmHg systolic and <90 mmHg diastolic targets for blood pressure in patients with CKD, with consideration for tighter targets in the setting of proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.